Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Crescent Biopharma, Inc. (CBIO) had Income from Continuous Operations of $-24.84M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-24.84M |
|
-- |
|
-- |
|
$26.36M |
|
$-26.36M |
|
$1.53M |
|
$-24.84M |
|
$-24.84M |
|
$-24.84M |
|
|
Income from Continuous Operations |
$-24.84M |
$-24.84M |
|
$-24.84M |
|
$-26.36M |
|
$-26.30M |
|
30.53M |
|
30.53M |
|
$-0.74 |
|
$-0.74 |
|
| Balance Sheet Financials | |
$179.01M |
|
$0.88M |
|
$3.75M |
|
$182.76M |
|
$18.54M |
|
-- |
|
$0.97M |
|
$19.50M |
|
$159.25M |
|
$163.25M |
|
$163.25M |
|
27.76M |
|
| Cash Flow Statement Financials | |
$-28.40M |
|
$-6.39M |
|
$-6.81M |
|
$213.30M |
|
$171.70M |
|
$-41.60M |
|
$8.08M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
9.66 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-26.79M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-15.60% |
|
-15.21% |
|
-13.59% |
|
-15.21% |
|
$5.88 |
|
$-0.88 |
|
$-0.93 |
|